Geoff Cook

Geoff Cook, CEO of Noom and a veteran in the health tech space, dives into the world of GLP-1 microdosing and its impact on weight loss and metabolic health. He shares his personal journey with microdosing, highlighting improved A1C and sustainable weight loss. The discussion delves into the safety and affordability of GLP-1 therapy, the significance of behavior change in maintaining results, and the innovative at-home blood testing that Noom offers for tracking metabolic progress. Geoff emphasizes the broader health benefits beyond appetite suppression, including reduced inflammation and improvements in overall well-being.

Geoff Cook, CEO of Noom, discusses the company's innovative approach to behavioral health and the shift towards GLP-1 microdosing. He emphasizes the importance of democratizing longevity medicine while navigating regulatory challenges and market dynamics. Geoff shares insights on the evolving healthcare landscape, including the integration of AI and personalized solutions. The conversation also touches on strategic partnerships, potential legal risks, and the future of health tech, as Noom adapts to compete in a saturated market.

Geoff Cook, CEO of Noom and a leader in digital health, joins the discussion about transforming weight loss into a holistic health journey. He reveals how Noom combines AI support, human coaching, and medications like GLP-1s to drive lasting behavior change. The conversation explores the intricacies of merging medication with lifestyle adjustments and highlights the challenges in accessing these treatments. Geoff also shares his vision for expanding beyond weight loss into broader wellness and longevity initiatives, paving the way for a healthier future.